Glepaglutide

Product Name: Glepaglutide

CAS No: 914009-86-2

Purity: 95%

Molar Mass: 4316.08

Chemical Formula: C197H325N53O55

Synonyms: ZP1848

Storage: Store at -20℃

Sequence: HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2

Target: GLP-2R

Application: Glepaglutide (CAS: 914009-86-2) is a novel peptide-based drug that functions as a glucagon-like peptide-2 (GLP-2) analog. GLP-2 is an intestinal hormone known for its role in promoting mucosal growth, enhancing nutrient absorption, and maintaining intestinal barrier function. Glepaglutide mimics the action of endogenous GLP-2 and is being developed for the treatment of short bowel syndrome (SBS), a condition characterized by inadequate intestinal absorption due to surgical resection, congenital defect, or disease. By stimulating intestinal growth and enhancing nutrient absorption, glepaglutide aims to improve intestinal function and reduce the dependence on parenteral nutrition in patients with SBS. In pharmaceutical research, glepaglutide represents a promising therapeutic option for addressing the underlying pathology of SBS and improving the quality of life for affected individuals. Clinical trials are ongoing to evaluate its safety, efficacy, and long-term effects in patients with SBS, with the goal of providing a much-needed treatment option for this challenging condition.

Reference:

Skarbaliene, J., Mathiesen, J. M., Larsen, B. D., Thorkildsen, C., & Petersen, Y. M. (2023). Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. BMC gastroenterology, 23(1), 79.

Agersnap, M. A., Sonne, K., Knudsen, K. M., Knudsen, C. B., & Berner-Hansen, M. (2022). Pharmacokinetics of glepaglutide, a long-acting glucagon-like peptide-2 analogue: a study in healthy subjects. Clinical Drug Investigation, 42(12), 1093-1100.